VIA Pharmaceuticals, Inc.
VIAP
$0.00
$0.000.00%
OTC PK
| 12/31/2010 | 09/30/2010 | 06/30/2010 | 03/31/2010 | 12/31/2009 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -54.64% | -54.57% | -43.43% | -20.27% | -15.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -68.52% | -59.79% | -57.09% | -42.10% | -33.45% |
| Operating Income | 68.52% | 59.79% | 57.09% | 42.10% | 33.45% |
| Income Before Tax | 41.83% | 73.65% | 52.35% | 32.13% | -0.47% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 41.83% | 73.65% | 52.35% | 32.13% | -0.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 41.83% | 73.65% | 52.35% | 32.13% | -0.47% |
| EBIT | 68.52% | 59.79% | 57.09% | 42.10% | 33.45% |
| EBITDA | 68.46% | 59.80% | 57.26% | 42.38% | 32.95% |
| EPS Basic | 42.91% | 74.20% | 53.47% | 33.91% | 2.00% |
| Normalized Basic EPS | 42.91% | 74.22% | 53.62% | 36.36% | 1.93% |
| EPS Diluted | 42.91% | 74.20% | 53.47% | 33.91% | 2.00% |
| Normalized Diluted EPS | 42.91% | 74.22% | 53.62% | 36.36% | 1.93% |
| Average Basic Shares Outstanding | 1.92% | 2.19% | 2.40% | 2.70% | 2.49% |
| Average Diluted Shares Outstanding | 1.92% | 2.19% | 2.40% | 2.70% | 2.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |